SJ, where did you see the confirmation that 9 patients were completed and 9 additional enrolled? I haven't seen that. It is good to finally see the daily market close being reported in a color other than red!
An earlier post seemed to imply that DNAbilize could be the "silver bullet" that would replace numerous chemo drugs in the future. If you look at the referenced slide closely you will see that the patient, who unfortuanately died, was an HIV patient who had a CML blast crisis and stable AML in addition to other serious autoimmune illnesses. People who die with HIV don't die from HIV but from numerous complications caused by the autoimmune disorder, cancers such as leukemia and lymphoma being a common complication. In any case the cocktail of drugs listed on the slide were not all there to treat his AML, in fact Gleevec is not indicated for treating AML but rather CML and ALL. We would be wrong to jump to the conclusion that DNAbilize will become the therapy of choice for physicians in the future for all cancers, replacing existing chemo drugs, although that would be great if it did!. In fact, when the BPTH CML studies begin it is very possible that Gleevec may be the drug used for a combination therapy if a combination study is submitted to the FDA so let's be careful not to jump to apparently logical conclusions that may not exist. I understand that the conclusion was made in an attempted to justify market capitalization but it can be mis-leading to the casual observer.
One thing about combination studies is that if they are as successful as we hope and they currently appear there would be every reason for a pharmaceutical company who makes the chemo drug used in the study to want to own BioPath either completely or in part, IMO.
